Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report)'s share price reached a new 52-week high on Thursday . The company traded as high as $36.35 and last traded at $30.24, with a volume of 16241600 shares traded. The stock had previously closed at $4.63.
Analyst Ratings Changes
A number of research analysts have weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Monopar Therapeutics in a research report on Friday, October 11th. They set a "buy" rating and a $50.00 target price for the company. HC Wainwright boosted their price objective on shares of Monopar Therapeutics from $2.00 to $6.00 and gave the stock a "buy" rating in a report on Wednesday, August 14th.
Get Our Latest Report on MNPR
Monopar Therapeutics Trading Up 605.4 %
The firm's fifty day moving average price is $3.97 and its 200-day moving average price is $3.62. The company has a market cap of $571.03 million, a P/E ratio of -74.04 and a beta of 1.26.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, research analysts forecast that Monopar Therapeutics Inc. will post -1.93 earnings per share for the current fiscal year.
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Featured Stories
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
